AllArticlesConferencesCOVID-19InterviewsMiscellaneousPresentationResearchUncategorizedAll Articles Conferences COVID-19 Interviews Miscellaneous Presentation Research Uncategorized RespiNet – A model for automated segmentation of lung structures.FLUIDDA introduces RespiNet, a model for automated segmentation of lung structures. At the ECR 2023 conference in Vienna, FLUIDDA presents their deep learning model for the segmentation of the lobes and airway… View ArticleNanopharm and FLUIDDA collaborate to enable alternative bioequivalence pathwaysNanopharm and FLUIDDA collaborate to enable alternative bioequivalence pathways for orally inhaled drug products To support generic drug companies in obtaining a market license for their orally inhaled drug products… View ArticleNovel outcome measures for cystic fibrosisNovel outcome measures for cystic fibrosis in a changing world Very recently Eline Lauwers, working for Fluidda in Belgium, defended a dissertation called: “Novel outcome measures for cystic fibrosis” to acquire… View ArticleRSNA 2022 Conference – Broncholab®Will you be attending RSNA 2022, November 27th – December 1st in Chicago? Then you have a possibility to learn all about Broncholab®. Fluidda will be present to explain all features… View ArticleWorld COPD day – The use of FRI technology in the combat against COPDThe exact prevalence of COPD worldwide is largely unknown, but estimates have varied from 7-19%. The Burden of Obstructive Lung Disease (BOLD) study found a global prevalence of 10.1%. According to WHO estimates, 65 million people… View ArticleERS2022 – Digital lung sound characteristics related to airflow turbulence intensityDuring the last ERS conference in Barcelona, Eline Lauwers, who recently obtained het PhD degree based on research partially conducted at Fluidda, presented a poster on her latest findings. She… View ArticleBroncholab® is now available in the UK until 2024Due to Brexit, the United Kingdom is updating its medical device regulations and introducing a new route (UKCA marking) to place medical devices on the UK market. The new legislative… View ArticleFluidda Magazine #3 – Improving healthcare in a post-pandemic world“In the respiratory space, the use of technology is still at a fairly low level. The gold standard is still spirometry. It is time to reassess and see if technology can be used in a way that really improves… View ArticlePresentation @ DATS 2022 – Patient specific computer models for inhalation therapyOn Friday October 21 Jan De Backer, CEO Fluidda will present at the “23. Deutsches Aerosol Therapie Symposium”, which will be held in the Hyperion Hotel in Munich, Germany. The… View ArticleERS2022 – Transcutaneous PCO₂ in COPD patientsDuring the last ERS conference in Barcelona, Wendel Dierckx, who previously worked for Fluidda, and momentarily works for and conducts research at the MedImprove lung rehabilitation clinic in Kontich, Belgium,… View ArticleIn-vitro/In-silico bio-equivalence trials as alternatives to clinical endpoint studies.On Friday October 7 at 2 PM EST, Jan De Backer CEO of Fluidda, will present at the RESCON-summit in New York. The presentation is entitled: “In-vitro/In-silico bio-equivalence trials as… View ArticleERS2022 Poster – The role of vascular density in pulmonary rehabilitation programsThe role of vascular density in pulmonary rehabilitation During the last ERS conference in Barcelona, Kris Ides, who works at the Antwerp University and in the MedImprove lung rehabilitation clinic… View ArticleFluidda Team Building – Belgian ArdennesFluidda organized a Team Building in the Belgian Ardennes for its staff. Because the company operates worldwide and is growing rapidly, several employees had never met each other in person,… View ArticlePRESS RELEASE – Fluidda and Aptar Pharma Exclusive CollaborationFluidda and Aptar Pharma Announce Exclusive Collaboration to Help Accelerate Regulatory Pathway for Orally Inhaled Products Kontich, Belgium, September 22, 2022 – Fluidda, leader in the field of Functional Respiratory… View ArticleFluidda Magazine #4 – FRI in Critical CareFRI in critical care: challenges and opportunities Functional Respiratory Imaging (FRI) did not have a place in critical care before the COVID-19 pandemic, but as healthcare systems were overloaded with… View ArticleERS 2022 – The possibilities of Broncholab and FluiddaAt the upcoming European Respiratory Society (ERS) 2022 conference, Fluidda is present with a booth and will be presenting 3 posters. From September 4th – 6th, we will exhibit at the annual conference… View ArticlePulmonary Thromboembolic Events in COVID-19In a recently published systematic literature review, members of PVRI Innovative Drug Development Initiative’s Sequelae of COVID-19 Workstream, including Fluidda CEO Jan De Backer and CSO Ben Lavon, sought to… View ArticleFluidda Magazine #3 – The potential of FRI in general pulmonologyThe potential of FRI in General Pulmonology “Technological advances have unleashed the potential to better treat prevalent lung diseases. Approaches like quantitative computerized tomography are increasingly used in routine care… View ArticleFluidda Magazine #3 – FRI advances patient care journey in PHFRI advances the patient care journey in Pulmonary Hypertension. “Innovative technologies are necessary to improve diagnosis and treatments in patients with pulmonary hypertension (PH). As a non-invasive tool that gives… View ArticleFluidda Magazine #3 – Pulmonary Vascular Disease.FRI is the missing link for pulmonary vascular disease State Dr. Raymond L Benza of The Ohio State University and Dr. Mardi Gomberg-Maitland of George Washington University in a recent interview in… View ArticleECR 2022 – Conference on Radiology in Vienna – May 13-17The ECR (European Congress of Radiology) is an international meeting and one of the leading yearly events in radiology, this year in Vienna. The ECR is one of the largest medical meetings… View ArticleBroncholab™ Offers Respiratory Solutions Optimize Treatment of Lung Patients – USA & EU.Broncholab™ is a platform where CT-scan data of individual persons can be uploaded and analysed with FRI-technology. The result of this analysis is then sent to the attending physician alone,… View ArticleSuccesvolle COVID-19 revalidatie en persoonlijke aandacht bij MedImproveThe Medimprove pulmonary rehabilitation facility, affiliated with Fluidda, is located in Kontich, Belgium.This interview with a COVID patient treated in this practice is therefore in Dutch language. Auteur: Patrick Marx… View ArticleBroncholab® Platform Obtains CE CertificateIn June 2022, Fluidda obtained a CE Certificate for its Broncholab platform and can be used by physicians in all countries of the European Union, Iceland, Liechtenstein and Norway. Broncholab® provides a number of Functional Respiratory Imaging… View ArticlePVRI 2022 – Congress on PVD in Athens, GreeceThe Pulmonary Vascular Research Institute (PVRI) yearly organizes a World Congress on Pulmonary Vascular Disease (PVD), this year from June 22-26 in Athens, Greece. The organization was established in 2006 to facilitate scientists, clinicians,… View ArticleFluidda Magazine #3 – FRI TechnologyWe proudly present the third Fluidda Magazine on FRI technology. Several key opinion leaders explain in this issue how FRI helps them to optimize the diagnosis and therapy of lung patients with… View ArticleRespiratory solutions for treatment of lung patients – BroncholabBroncholab offers respiratory solutions to optimize treatment of individual lung patients Broncholab™, developed and implemented by Fluidda, is a platform where CT-scan data of individual persons can be uploaded and… View ArticleCityBiz Interview with Jan De Backer – CEO of FluiddaOn the 23rd of May, Jan De Backer – CEO of Fluidda had an interview with Edwin Warfield – CEO of Citybiz. Interview questions: Introduction | Please provide an introduction to… View ArticleDriving Change through Healthcare InnovationThe world of healthcare is ripe for change, and innovation is the key to driving better patient outcomes. However, a concerted effort is required to ensure that this change actually… View ArticleAnnual ALA Lung Force Walk – 21th May 2022 NYCFluidda is present at the annual ALA Lug Force Walk , Saturday May 21 in New York City. The annual American Lung Association Lung Force walk will take place in… View ArticleATS 2022 – Booth #735The ATS International Conference is the home of pulmonary, critical care, and sleep professionals, from those in the earliest stages of their careers to those whose research or strides in… View ArticleMEDIMPROVE – A new private clinic for lung revalidation with FRITo address the need for better chronic respiratory care, Prof De Backer, emeritus Professor Pulmonology at the University of Antwerp and Chairman of The board of FLUIDDA NV, has opened a private clinic… View ArticleWorld Asthma Day 2022Fluidda endorses World Asthma Day. On World Asthma Day (May 3, 2022) and throughout May, people with asthma and organizations dedicated to asthma control and education join to increase awareness… View ArticleISO 13485 2016 Certification Acquired For Quality Management SystemFluidda acquired an ISO 13485 2016 certification for its Quality Management System. We are pleased to announce that Fluidda’s Quality Management System now has an ISO 13485 2016 certificate. We… View ArticleProf. Krestin joins Fluidda’s board of directorsINTRODUCTION Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked… View ArticleFluidda – ISHLT 2022Fluidda will be present at the annual meeting of the ISHLT The ISHLT (The International Society for Heart and Lung transplantation) is pleased to announce that its 42nd Annual Meeting… View ArticleMarch 24: World Tuberculosis DayEach year, World Tuberculosis (TB) Day is commemorated on March 24 to raise public awareness about the devastating health, social and economic consequences of TB, and to step up efforts to end… View ArticleLung deposition measured by FRI of inhaled LAMA via standard jet nebulizer or DPILung deposition measured by Functional Respiratory Imaging (FRI) of inhaled LAMA via standard jet nebulizer or DPI. In a recently published study, FRI respiratory imaging was used to determine deposition patterns for… View ArticleFRI: in the transition from research to clinical practiceFunctional Respiratory Imaging (FRI): in the transition from research to clinical practice? “Quantitative imaging of the airways, for example with functional respiratory imaging (FRI), is evolving from a research tool towards clinical… View ArticleFRI offers early and rapid detection of lung diseases – Fluidda Magazine #2FRI offers early and rapid detection of lung diseases “Lung diseases often lead to irreversible damage. Early detection and start of the right treatment are therefore crucial. Functional Respiratory Imaging (FRI) makes rapid diagnosis and treatment possible…. View ArticleSolving the mystery of long COVID – Fluidda Magazine #2Imaging of the pulmonary vasculature is crucial for our understanding of the short- and long-term consequences of COVID-19 Prof. William Li, president and medical director of the Angiogenesis Foundation, explains during an interview in… View ArticleFunctional Respiratory Imaging can predict the course of COVID-19Functional Respiratory Imaging (FRI) quantifies and visualizes the distribution of blood vessels in the lungs in great detail. This simple model, which combines the results of the imaging with the… View ArticleThe potential of using FRI to improve healthcare now and in the future – The vision of Fluidda’s CEOThe second edition of the Fluidda Magazine on FRI was recently published, containing several articles about how FRI is being used in clinical practice by radiologists and pulmonologists, especially during… View ArticleThe Fluidda team wishes you a wonderful and healthy 2022!The association of abnormal pulmonary vasculature on CT scan for COVID-19 infection and decreased diffusion capacityIn a recently published study Functional Respiratory Imaging (FRI) was used to retrospectively study the association of abnormal pulmonary vasculature on CT scan for COVID-19 infection with decreased diffusion capacity in follow… View ArticlePresentation CEO Fluidda at DDL 2021 conference – Functional Respiratory Imaging in times of COVID19Presentation CEO Fluidda at DDL 2021 conference: Functional Respiratory Imaging in times of COVID19 Tomorrow, December 9, Fluidda’s CEO Jan De Backer will present at the virtual conference Drug delivery… View ArticleRSNA 2021 – Imaging quantification like Broncholab trending topic at RSNA conferenceDuring the just finished RSNA (Radiological Society of North America) congress, Fluidda introduced its new medical device called Broncholab to the radiologists for the first time. Broncholab is a diagnostic support tool to detect and to improve therapy of… View ArticleRSNA 2021 || Fluidda introduces Broncholab application || November 28th – December 2nd || ChicagoFluidda introduces Broncholab application during the RSNA conference, Nov 28 – Dec 2, Chicago Broncholab uses a quantitative imaging tool called Functional Respiratory Imaging (FRI), which gives insights into the… View ArticleRSNA 2021 – Visit our Booth #4335 and learn all about BroncholabAre you attending RSNA 2021? Visit the Fluidda Booth #4335 and learn all about Broncholab. Fluidda will introduce their new Medical Device Broncholab at the RSNA Conference. Broncholab enables accurate… View ArticleFRI – Understanding the link between pulmonary vasculature abnormalities and DCLO in COVID-19FRI used to understand the link between pulmonary vasculature abnormalities and DCLO in COVID-19 In a recent article, Prof Daniel Salerno, Prof Victor Kim and colleagues used Functional Respiratory Imaging to better understand the crucial… View ArticleFRI improves patient selection for mandibular advancement device treatmentIn a recent published study Functional Respiratory Imaging (FRI) was used to assess Mandibular advancement devices (MAD) mechanisms. MAD are a non-invasive treatment option for patients with obstructive sleep apnea… View ArticleThe features and advantages of Fluidda’s FRI technologyFLUIDDA is the world leader in the field of Functional Respiratory Imaging. This technique combines HRCT scans and Computational Fluid Dynamics technology, enabling the assessment of treatment responses, and helping physicians to make… View ArticleThe Seven pillars of SAD in Asthma and COPDIn a recent publication in CHEST Journal, the importance of the small airways and their contribution to symptoms of asthma and COPD are discussed. Significant small airways dysfunction can be found… View ArticleFluidda’s Images Featured On Cover European Respiratory JournalFluidda’s vascular lung images featured on the cover of the digital European Respiratory Journal The European Respiratory Journal published a study (ERJ, impact factor 16.67) looking at the pulmonary blood… View ArticleFluidda Amongst Top Medical Imaging Providers 2021Healthcare Tech Outlook, a leading Healthcare technology print magazine, which provides a knowledge network for Healthcare Industry experts, awarded Fluidda as a “Top Ten” Medical Imaging Provider of the year… View ArticleNew technique offers better lung care – Campaign The GuardianWe supported the Respiratory Health campaign that launched on Launch Date within the Guardian newspaper and online at https://bit.ly/3q3yTG6. Respiratory Health looked at key respiratory conditions, new innovations and the… View ArticleFluidda’s Broncholab issued Authorization with Conditions by Health Canada for Use in Relation to COVID-19In March 2020 Fluidda’s medical device called Broncholab was introduced in the USA. It is a diagnostic support tool to detect and to to improve therapy of lung diseases based on FRI technology. Broncholab will initially… View ArticleThe added value of FRI, explained by Dr. Muhunthan ThillaiDr. Muhunthan Thillai is a pulmonologist at Cambridge University, specialized in pulmonary fibrosis; and co-founder and CEO of Qur8, an imaging platform for analyzing large clinical sets of data. He is… View ArticleThe advent, value and place of QCT, Interview with Dr. Hoesein, UMCU.In the recently published “Fluidda’s Magazine on FRI”, Dr. Firdaus Hoesein, radiologist at the University Medical Centre Utrecht, was interviewed about his experiences with FRI and his expectations for the use… View Article“The need to Measure”, an interview with Dr. Langton on FRIIn the recently published “Fluidda’s Magazine on FRI”, Dr. Langton, pulmonologist at the University of Melbourne specialized in bronchial thermoplasty treatment, was interviewed about his experiences with FRI and his… View ArticleFluidda interviewed in “Precision Medicine” issue Pharma Focus AsiaIn the latest issue of the magazine Pharma Focus Asia, dedicated to precision medicine and personalizing health outcomes, the founders of Fluidda were interviewed. In this interview titled: “ Functional… View ArticleNovel FRI parameter analyzing the pulmonary vascular bed accurately predicts outcomes in COVID-19 disease, and can be decisive in choice of therapy.In a recent publication in the European Respiratory Journal (ERJ) by Morris et al. a retrospective analysis was performed of chest CT scans of 313 COVID-19 positive and 195 COVID-19 negative patients seeking acute medical care. From… View ArticleOver 5000 COVID-19 patients already analyzed with Fluidda’s new blood vessel volume FRI parameterWe are pleased to announce that CT scans of more than 5000 COVID-19 patients from all corners of the world have been analyzed with Fluidda’s recently developed BVX parameter! The BVX parameter… View ArticleDrug delivery and lung deposition using the Aerosphere™ inhaler, a study performed with FRI technology.Metered dose inhalers (MDI’s) are one of the most common device types for delivering inhaled therapies. However, there are several technical challenges in development and drug delivery of these medications…. View ArticleFluidda joins P4O2 ConsortiumPrevention is the key to healthy lungs.The quality of life for patients with chronic lung diseases like asthma, COPD, and lung cancer can- and should be improved. The Dutch consortium… View ArticlePredicting Lung Deposition of extrafine ICS Containing Fixed Combinations COPD patients using FRI in an in silico study.In a recent study by Usmani et al. , FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered… View ArticleNew FRI Article: Cluckers et al: Interstitial lung disease in systemic sclerosisFRI is able to differentiate moderate to severe versus limited disease and to detect disease progression in systemic sclerosis. Systemic sclerosis–associated ILD accounts for up to 20% of mortality in these patients… View ArticleTV News Show – January 14th – FRI in COVID-19 longhaulersFRI on PBS news hour: Medical community scrambles to understand COVID-19 ‘long haulers’ During a news item on PBS news hour, January 13, COVID-19 “long haulers” were discussed. Long haulers are COVID-19 patients… View ArticleFluidda’s COVID-19 consortiumToday, one year into the COVID-19 pandemic, we live in a changed world. With over a million deaths and many millions suffering long-term disability as a result of lasting damage… View ArticlePress release – Results PINTA trial Galapagos on IPF while using FRIGalapagos Announces Positive Topline Results in Phase 2 Study Using FRI Imaging Parameters While Investigating New Medication for IPF Patients. The PINTA trial was a randomized, double-blind, placebo-controlled trial investigating… View ArticleVisualisation FRI study – Effect lung deposition by adding an Aerochamber when using a pMDI in COPDEvaluations of inhaler use have demonstrated that mishandling of pMDIs (Pressurized Meter Dose Inhalers) is commonplace. One of the most common errors is the failure to coordinate inhalation with actuation… View ArticleFRI Biomarker OverviewThe added value of FRI in treating lung diseases. Fluidda developed a large number of HRCT-derived imaging parameters, based on its proprietary Functional Respiratory Imaging (FRI) technique, to generate very… View ArticleWorld COPD-Day 2020The use of Fluidda’s FRI technology in the combat against COPD. The exact prevalence of COPD worldwide is largely unknown, but estimates have varied from 7-19%. The Burden of Obstructive Lung Disease (BOLD) study… View ArticleBVX scans with COVID-patients – Delta HospitalDelta Hospital uses new imaging technology for better triage and optimal treatment of COVID-19 patients. Due to the very large number of Corona patients who now report daily for hospitalization,… View ArticlePoster CHEST 2020: AZ studie Maarten van den BergeFRI assessment of a fixed Triple Therapy (Bud/Gly/FF) and a fixed Dual Therapy (Gly/FF) in patients with COPD In a study presented as a poster at the virtual Chest conference, FRI was used… View ArticleFLUIDDA’s Online Site Training Course For Clinical Research SitesFluidda’s Online Site Training Course For Clinical Research Sites goes ” LIVE” For years Fluidda educates pulmonologists and CT-scanning personnel “on site” how to perform HRCT-scans that can be used in Clinical Trials… View ArticleThe Perfect StormTime for a paradigm shift in lung function research? The golden age of pulmonary function testing began in the 1920s, driven by the increasing prevalence of occupational lung disease and resulting interest… View ArticleFluidda’s FRI-activities are at “Full Speed” during this COVID-19 pandemicFluidda’s FRI-activities are at “Full Speed” during this COVID-19 pandemic The COVID-19 crisis has had a tremendous impact on the initiation and progression of clinical research around the world and… View ArticleP4O2 press release Netherlands Respiratory Society (NRS)A Public-private consortium P4O2 (Precision Medicine for more Oxygen) investigates risk factors for developing lung damage and chronic complaints after COVID-19. Many patients who have had COVID-19 continue to have… View ArticleAssessing short term effects of Orkambi on lung function in CF patientsFRI used to assess short-term effects of Orkambi on lung function in patients with CF homozygous for F508de The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator Orkambi (lumacaftor-ivacaftor) has shown modest benefits… View ArticleFluidda’s clinical research on COVID-19 in Belgian HCP-magazine.On July 1, Chiesi and Fluidda organized an international webinar for pneumologists and other health professionals, discussing the use of Functional Respiratory Imaging during the covid-19 pandemic in three different… View ArticleERS 2020 – Lung Deposition of Two Bronchodilators in Subjects With COPDLung Deposition of Two Bronchodilators in Subjects with COPD When Administered via Standard Jet Nebulizer or HandiHaler® Using FRI. During the ERS Congress 2020, a poster was presented comparing lung deposition of… View ArticleERS 2020 – FRI shows significant regional ventilation defects in COPDFunctional Respiratory Imaging (FRI) shows significant regional ventilation defects in COPD patients as compared to healthy patients Ventilation defects in COPD are associated with reduced exercise tolerance and worse quality… View ArticleERS 2020 – Ventilation-perfusion measures based on FRI correlates with exercise tolerance and PRO’s in COPDVentilation-perfusion measures based on FRI correlates with exercise tolerance in COPD COPD affects the lungs in many ways. A common problem is reduced ventilation-perfusion (V/Q) values caused by airway disease… View ArticleFRI identifies redistribution of pulmonary blood flow in patients with COVID-19Functional respiratory imaging identifies changes in pulmonary blood flow in patients with COVID-19 An common observation is that some patients with COVID-19 have normal lung compliance but significant hypoxaemia different from… View ArticleUse of FRI in deposition of inhaled lip. cyclosporin in BOSUse Of Functional Respiratory Imaging (FRI) To Explore Drug Delivery And Lung Deposition Of Inhaled Liposomal Cyclosporine A (L-CsA-i) In Patients After Lung Transplantation (LTx) FRI-based biomarkers have been investigated as… View ArticleSummer Holiday Card 2020Webcast Mundipharma – July 15th 2020On July 15, from 6 – 7.30 pm GMT, Mundipharma organizes a webinar for pulmonologists and other interested HCP’s on respiratory topics in the focus of interest, such as the… View ArticlePodcast with Dr. Rola on the clinical possibilities of FRIOn July 3rd, Fluidda’s CEO Dr Jan De Backer had a podcast interview with Dr Philippe Rola, president of the critical care unit at the Santa Cabrini Hospital in Montreal,… View ArticleWebinar – Lessons Learned from COVID-19 – Now Available OfflineThis week a very high rated webinar was broadcast where the latest findings on COVID-19 research with FRI-technology was presented by prominent pulmonologists and radiologists from all over the world…. View ArticleWebinar – Lessons learned from the COVID-19 crisisLessons learned from the COVID-19 crisis. This is the title of a webinar Fluidda and Chiesi will broadcast on July 1st at 8 pm CET for interested pulmonologists and other… View ArticleAssessment of small pulmonary blood vessels in COVID-19 patients using HRCTNew publication on FRI: Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT Mounting evidence supports the role of pulmonary hemodynamic alterations in the pathogenesis of COVID-19. Building… View ArticleComparison inhalation with pMDI and pMDI/spacer on drug delivery in the lung using FRI technologyPublished in: Am J Respir Crit Care Med 2020;201:A5689 Authors: J. Suggett1, V. Kushnarev(1) , C. Van Holsbeke (2) , S. Van Steen(2) , B. Mignot(2) 1) Trudell Medical International, London,… View ArticleTheoretical Model of the Pathophysiology of COVID-19 using FRI-data in EMCRIT podcastDuring an EMCRIT podcast last week. Dr. Farid Jalali (Long beach CA) laid out a theoretical framework for the pathophysiology of the lung effects of COVID-19. Take Home Points from this podcast… View ArticleFRI assessment of Glycopyrrolate and FF pMDIs using co-delivery technology in COPDNew published article: FRI assessment of glycopyrrolate and formoterol fumarate pMDI formulations using co-suspension delivery technology in COPD. Understanding lungs and lung diseases has never been more important than in… View ArticleEffectiveness of a new mobile HFCWO device for airway clearance in CF patientsFluidda studied the effectiveness of a new mobile HFCWO device for airway clearance in CF patients. High-frequency chest wall oscillation (HFCWO) is a commonly used airway clearance technique for cystic… View ArticleFull Broadcast – Kathy Ireland InterviewWorldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its viewers with an in-depth opportunity to find solutions to industry problems from some of… View ArticleCOVID-19 – Kathy Ireland InterviewWorldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its viewers with an in-depth opportunity to find solutions to industry problems from some of… View ArticleDiseases and Spirometry – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program: Worldwide Business with Kathy Ireland. (Part three) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleInterview AnnouncementLIVE STREAM ANNOUNCEMENT: Fluidda’s CEO will be interviewed on USA television. Dr. Jan De Backer, Fluidda CEO, was recently interviewed about the company’s work on facilitating diagnosis and treatment of… View ArticleOur consortium on COVID-19LET’S TACKLE COVID-19 IN A CONSORTIUM! In an ongoing effort, Fluidda is collecting several batches of HRCT-scans of COVID19-patients to analyze them with their Functional Respiratory Imaging (FRI) technology in… View ArticleWhat is FRI – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program Worldwide Business with Kathy Ireland. (Part two) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleOur mission and vision – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program Worldwide Business with Kathy Ireland. (Part one) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleAntwerp biotech company improves lung damage predictability using 3D scans.By Pieter Haeck, reporter Belgian newspaper “De Tijd”. April 7, 2020 What is the prognosis for someone infected with the corona virus? Will the patient deteriorate quickly or not? The… View ArticleNew 3D-printed connector for non-invasive ventilation developed by Materialise and Fluidda.Materialise and Fluidda worked together in the development of a 3D-printed Non-Invasive PEEP Mask to Alleviate Ventilator Shortage For several years. Materialise, a Belgian 3D printing company with one of… View ArticleMedtech goes to war with COVID-19 (DeviceTalks Weekly)In the most recent Device Talk podcast, Jan de Backer, CEO of Fluidda, was interviewed about medtech’s essential role in the escalating war against COVID-19. He explains how Fluidda’s proprietary… View ArticleFDA clears Fluidda’s Broncholab platform for use in Clinical PracticeThe US Food and Drug Administration provided market clearance to Fluidda for its Broncholab platform. Broncholab provides a number of Functional Respiratory Imaging (FRI) parameters to physicians via an online… View ArticleAirway volume measurement with FRI identifies IPF progressionIdiopathic pulmonary fibrosis (IPF) is a progressive disease with unclear etiology. IPF patients decline with heterogeneous trajectories. The ability to determine an individual’s disease course is limited to pulmonary function measurement… View ArticleFluidda’s investigational network of FRI sitesFluidda’s investigational FRI sites are located all over the world, enhancing clinical research with FRI locally. Fluidda is the world leader in the field of Functional Respiratory Imaging. This technique combines HRCT scans,… View ArticleFDA – FRI acknowledged important tool for investigating depositionIn a recent article, the Food and Drug Administration (FDA) mentioned Fluidda’s FRI technology as an important tool to investigate regional drug deposition of the extrathoracic region, especially to measure… View ArticleFRI may be able to help in optimizing lung tumor treatmentFunctional Respiratory Imaging (FRI) may be able to help in optimizing lung tumor treatment. It is not enough to only look at nodule size as one parameter to determine treatment… View ArticleBronchial thermoplasty increases airway volumeIn a recent study, 10 patients with unstable, severe asthma were treated with Bronchial Thermoplasty (BT) of the left lung, while the right lung was used as an internal control. Changes in… View ArticleEffectiveness of a mobile HFCWO device for airway clearanceHigh Frequency Chest Wall Oscillation (HFCWO) is a commonly used airway clearance technique for Cystic Fibrosis (CF) patients. At ERS 2019 in Madrid, a poster was presented on this topic…. View ArticleFiGHT Australian wildfiresFluidda helps firefighters! Because of climate change, there is an increasing number of spontaneous wildfires all over the world, as we are now unfortunately experiencing in Australia. Fluidda, the company… View ArticleThe usage of AI in medical imagingAt the ERS 2019 conference in Madrid, our Director of Research and Development of Fluidda, gave his opinion on how Artificial Intelligence can help to improve the prediction of respiratory… View ArticleHappy Holidays 2019 – 2020Fluidda wishes you happy holidays and an inspiring 2020!PhD thesis on using AI in combination with FRIAt the University of Antwerp, Maarten Lanclus, Research & Development director of Fluidda, successfully defended his thesis on the topic of using Artificial Intelligence (A.I.) in combination with FRI to enhance… View ArticleOur corporate responsibility project – ERS 2019At ERS 2019, Cedric van Holsbeke, Chief Technology Officer of Fluidda talks about Fluidda’s corporate responsibility project. Laptops, previously used for patient training purposes and training of clinical sites, have been donated by… View ArticleDDL Conference 11 – 13 December EdinburghThe Drug Delivery to the Lungs (DDL) Conference provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation. Fluidda is actively involved in… View ArticleThe effects of particle size in deposition projects – ERS 2019During the ERS 2019 two posters were presented on the deposition of extrafine vs. non-extrafine formulations of different respiratory drugs in different inhalation devices. Both studies were conducted with Functional… View ArticleHow does FRI compare to spirometry?Functional Respiratory Imaging (FRI) parameters can reduce the number of patients required in clinical trials up to sixteen times compared with spirometry while maintaining adequate power and statistical significance. FRI… View ArticleThe value of Fluidda in respiratory clinical research – ERS 2019Prof. W. De Backer, Chairman of the Board of Fluidda nv, was interviewed at the ERS 2019 conference in Madrid about the insights that lead to the founding of the… View ArticleThe advantages of using FRI in clinical trials – ERS 2019Glenn Leemans, Fluidda’s Chief Operative Officer (COO), was interviewed at the ERS 2019 conference in Madrid. In this interview, Glenn explains why Fluidda’s proprietary functional respiratory imaging (FRI) technique can… View ArticleRSNA 2019 – Annual Congress 1st – 6th December ChicagoFluidda will be present at the annual congress of the Radiological Society of North America (RSNA). This year’s congress will take place during 1-6 December in Chicago, Illinois . The RSNA… View ArticleUsing FRI to detect early wildfire exposure on lung developmentDuring the ERS 2019 conference, Fluidda presented the results of a study which investigated that FRI (Functional Respiratory Imaging) parameters can be a sensitive tool to detect early-life wildfire smoke… View ArticleUnderstanding Mucus in Chronic Obstructive Pulmonary Disease (COPD)Mucus plays a major role in Chronic Obstructive Pulmonary Disease (COPD), especially in the Chronic Bronchitis phenotypes. Mucus increases airway resistance making it harder for the patient to breath. At… View ArticleThe highlights of ERS 2019 by Jan De Backer, CEO of FluiddaAt ERS 2019, Jan de Backer, CEO of Fluidda, explains why during the past years, the treatment of lung diseases is shifting from using more common bronchodilatators to more personalized… View ArticleERS 2019 – We are present with our booth and 7 postersFrom September 28 until October 2, Fluidda will exhibit at the annual conference of the European Respiratory Society (ERS) in Madrid, Spain. During this conference, Fluidda will present 7 posters on… View ArticleFluidda will be present at the Annual Drug Discovery & Development Symposium on Pulmonary Vascular DiseaseThis year’s symposium will take place in Paris on July 1-2. Each year the meeting brings leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial… View ArticleFluidda attends the International Conference of Medical imaging with Deep LearningDuring July 8-10 the International Conference of Medical imaging with Deep Learning takes place in London. The FLUIDDA team, specialised in using advanced A.I. algorithms to extract clinically relevant regional… View ArticleBronchial thermoplasty increases airway volume measured by Functional Respiratory Imaging (FRI)In a recently published study (click here for full article) 10 patients with unstable, severe asthma were treated with bronchial thermoplasty of the left lung, while the right lung was used as an… View Article
